Efficacy and safety of rozanolixizumab treatment cycles in patients with generalized myasthenia gravis: Final pooled analysis of Phase 3 studies

Key Points

• Efficacy of rozanolixizumab treatment cycles showed significant improvement in myasthenia gravis symptoms.
• The safety profile demonstrated manageable adverse events during the phase 3 studies.
• Analysis pooled data from multiple trials to ensure robust insights on treatment effects.
• Further investigation may lead to broader applications and standards in managing myasthenia gravis.